Axsome Therapeutics, Inc.
AXSM
Rang in Aktien
#2389
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Aktienkurs
$157.29
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$8.24B
Veränderung (1 Tag)
-2.78%
Veränderung (1 Jahr)
22.94%
Land
US
Handel Axsome Therapeutics, Inc. (AXSM)
Kategorie
Healthcare
EPS für Axsome Therapeutics, Inc. (AXSM)
EPS zum June 2026 TTM: $-3.75
Laut den aktuellen Finanzberichten und dem Aktienkurs von Axsome Therapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-3.75. Am Ende des Jahres 2023 betrug das EPS $-5.27 eine Steigerung gegenüber dem EPS von 2022, das $-4.60 betrug.
EPS-Verlauf von Axsome Therapeutics, Inc. von 2013 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-3.75 | -37.40% |
| 2024 | $-5.99 | 13.66% |
| 2023 | $-5.27 | 14.57% |
| 2022 | $-4.60 | 32.56% |
| 2021 | $-3.47 | 22.61% |
| 2020 | $-2.83 | 38.05% |
| 2019 | $-2.05 | 78.26% |
| 2018 | $-1.15 | -9.45% |
| 2017 | $-1.27 | -10.56% |
| 2016 | $-1.42 | 61.36% |
| 2015 | $-0.88 | 87.23% |
| 2014 | $-0.47 | 67.86% |
| 2013 | $-0.28 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -561.87% |
US
|
|
| $-7.98 | 112.80% |
US
|
|
| $-5.29 | 41.07% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -839.73% |
NL
|
